FI104985B - Hiivan muokkausjärjestelmä, joka käsittää muokkauskohdan vieressä negatiivisesti varautuneen aminohapon - Google Patents
Hiivan muokkausjärjestelmä, joka käsittää muokkauskohdan vieressä negatiivisesti varautuneen aminohapon Download PDFInfo
- Publication number
- FI104985B FI104985B FI914125A FI914125A FI104985B FI 104985 B FI104985 B FI 104985B FI 914125 A FI914125 A FI 914125A FI 914125 A FI914125 A FI 914125A FI 104985 B FI104985 B FI 104985B
- Authority
- FI
- Finland
- Prior art keywords
- glu
- leu
- polypeptide
- ala
- asp
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 91
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 83
- 230000004048 modification Effects 0.000 title claims description 22
- 238000012986 modification Methods 0.000 title claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 99
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 93
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 90
- 229920001184 polypeptide Polymers 0.000 claims abstract description 89
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 73
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 68
- 229960004405 aprotinin Drugs 0.000 claims abstract description 64
- 108010039627 Aprotinin Proteins 0.000 claims abstract description 54
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000002243 precursor Substances 0.000 claims abstract description 36
- 102000004877 Insulin Human genes 0.000 claims abstract description 18
- 108090001061 Insulin Proteins 0.000 claims abstract description 18
- 229940125396 insulin Drugs 0.000 claims abstract description 18
- 230000006337 proteolytic cleavage Effects 0.000 claims abstract description 12
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 5
- 230000004927 fusion Effects 0.000 claims abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 20
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical group C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims description 16
- 239000004026 insulin derivative Substances 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical group CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 claims description 6
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 101150071434 BAR1 gene Proteins 0.000 claims description 3
- 101100378536 Ovis aries ADRB1 gene Proteins 0.000 claims description 3
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 claims description 3
- -1 factor ΧΙΠ Proteins 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- PXXLQQDIFVPNMP-UHFFFAOYSA-N 3-(diethylcarbamoyl)benzoic acid Chemical compound CCN(CC)C(=O)C1=CC=CC(C(O)=O)=C1 PXXLQQDIFVPNMP-UHFFFAOYSA-N 0.000 claims description 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 2
- 108010023321 Factor VII Proteins 0.000 claims description 2
- 102400000321 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108010006025 bovine growth hormone Proteins 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 229940012413 factor vii Drugs 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- VSMYBNPOHYAXSD-GUBZILKMSA-N Asp-Lys-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O VSMYBNPOHYAXSD-GUBZILKMSA-N 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 claims 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 108010049041 glutamylalanine Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 238000012545 processing Methods 0.000 abstract description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 74
- 235000018102 proteins Nutrition 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 67
- 239000013612 plasmid Substances 0.000 description 59
- 239000012634 fragment Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 239000000600 sorbitol Substances 0.000 description 16
- 238000010276 construction Methods 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 108700005078 Synthetic Genes Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000007222 ypd medium Substances 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 101150033985 TPI gene Proteins 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 101150028074 2 gene Proteins 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000713596 Homo sapiens T-box transcription factor TBX19 Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100036773 T-box transcription factor TBX19 Human genes 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 101150046681 atp5if1 gene Proteins 0.000 description 2
- 239000007998 bicine buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000007261 sc medium Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000954 titration curve Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 description 1
- 101000679359 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase TPTE2 Proteins 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101100491597 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-6 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102100022577 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase TPTE2 Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000988 hyperfibrinolytic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 108700030835 yeast plasmid REP Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Processing Of Solid Wastes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Particle Accelerators (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK105489 | 1989-03-03 | ||
| DK105489A DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Polypeptid |
| DK494189A DK494189D0 (da) | 1989-10-06 | 1989-10-06 | Polypeptid |
| DK494189 | 1989-10-06 | ||
| PCT/DK1990/000058 WO1990010075A1 (en) | 1989-03-03 | 1990-03-01 | Yeast processing system comprising a negatively charged amino acid adjacent to the processing site |
| DK9000058 | 1990-03-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI914125A0 FI914125A0 (fi) | 1991-09-02 |
| FI104985B true FI104985B (fi) | 2000-05-15 |
Family
ID=26065137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI914125A FI104985B (fi) | 1989-03-03 | 1991-09-02 | Hiivan muokkausjärjestelmä, joka käsittää muokkauskohdan vieressä negatiivisesti varautuneen aminohapon |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US5395922A (de) |
| EP (1) | EP0461165B2 (de) |
| JP (1) | JP2609367B2 (de) |
| KR (1) | KR970005928B1 (de) |
| AT (1) | ATE110414T1 (de) |
| AU (1) | AU624694B2 (de) |
| CA (1) | CA2050336C (de) |
| CZ (1) | CZ285239B6 (de) |
| DD (1) | DD296965A5 (de) |
| DE (1) | DE69011853T3 (de) |
| DK (2) | DK105489D0 (de) |
| ES (1) | ES2062514T5 (de) |
| FI (1) | FI104985B (de) |
| HU (2) | HU215538B (de) |
| IE (1) | IE66469B1 (de) |
| IL (1) | IL93609A (de) |
| NO (2) | NO304236B1 (de) |
| NZ (1) | NZ232742A (de) |
| PL (1) | PL163532B1 (de) |
| RU (1) | RU2194758C2 (de) |
| UA (1) | UA27706C2 (de) |
| WO (1) | WO1990010075A1 (de) |
| ZA (1) | ZA901476B (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591603A (en) * | 1987-08-28 | 1997-01-07 | Novo Nordisk A/S | Process for preparing aprotinin and aprotinin analogs in yeast cells |
| DK105489D0 (da) * | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| JPH04507341A (ja) * | 1989-05-19 | 1992-12-24 | バイオテクノロジー リサーチ アンド ディヴェロプメント コーポレーション | ｉｎ ｖｉｖｏ翻訳後修飾部位を有する融合タンパク質及び製造及び精製方法 |
| GB9015825D0 (en) * | 1990-07-18 | 1990-09-05 | Ciba Geigy Ag | In vitro processing of fusion proteins |
| DK300090D0 (da) * | 1990-12-19 | 1990-12-19 | Novo Nordisk As | Fremgangsmaade til fremstilling af leadersekvenser |
| GB9106185D0 (en) * | 1991-03-22 | 1991-05-08 | Wellcome Found | Biological control agents |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FI92601C (fi) * | 1992-03-11 | 1994-12-12 | Marja Makarow | Menetelmä hyötyproteiinien erittämiseksi hiivoista |
| US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
| DE4417353A1 (de) * | 1994-05-18 | 1996-01-25 | Bayer Ag | Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz |
| ZA954983B (en) * | 1994-06-17 | 1996-02-14 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| US5861267A (en) * | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
| ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| DE19629982A1 (de) | 1996-07-25 | 1998-01-29 | Bayer Ag | Aprotinin-Varianten mit verbesserten Eigenschaften |
| WO1998025963A1 (en) | 1996-12-13 | 1998-06-18 | Chiron Corporation | Analysis and separation of platelet-derived growth factor proteins |
| JP4187796B2 (ja) * | 1996-12-20 | 2008-11-26 | ノボ ノルディスク アクティーゼルスカブ | 酵母で発現されたｎ末端伸長タンパク質 |
| EP0954589A1 (de) * | 1997-01-24 | 1999-11-10 | Novo Nordisk A/S | Sythetische signalpeptid-sequenzen. |
| US6046000A (en) * | 1997-11-07 | 2000-04-04 | Millennium Biotherapeutics, Inc. | Method for identifying genes encoding signal sequences |
| JP2003525570A (ja) | 1998-01-23 | 2003-09-02 | ノボ ノルディスク アクティーゼルスカブ | 酵母において所望のポリペプチドを産生する方法 |
| CN1415019A (zh) | 1999-12-29 | 2003-04-30 | 诺沃挪第克公司 | 用于生产在酵母中具有改进发酵产量的胰岛素前体和胰岛素前体类似物的方法 |
| AU2001259063A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7595172B2 (en) | 2001-07-24 | 2009-09-29 | Novo Nordisk A/S | Method for making acylated polypeptides |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1463751B1 (de) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albuminfusionsproteine |
| CA2498017C (en) | 2002-09-13 | 2016-06-14 | Cornell Research Foundation, Inc. | Using mutations to improve aspergillus phytases |
| EP1594530A4 (de) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Albuminfusionsproteine |
| EP1687428A1 (de) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Verfahren zur herstellung von acyliertem insulin |
| WO2005054291A1 (en) | 2003-12-03 | 2005-06-16 | Novo Nordisk A/S | Single-chain insulin |
| ES2368500T3 (es) | 2005-08-16 | 2011-11-17 | Novo Nordisk A/S | Método para producir polipéptidos de insulina maduros. |
| ATE482977T1 (de) | 2006-02-27 | 2010-10-15 | Novo Nordisk As | Insulinderivate |
| US20080026376A1 (en) | 2006-07-11 | 2008-01-31 | Huaming Wang | KEX2 cleavage regions of recombinant fusion proteins |
| US8198046B2 (en) | 2006-07-11 | 2012-06-12 | Danisco Us Inc. | KEX2 cleavage regions of recombinant fusion proteins |
| CN101541830A (zh) | 2006-09-22 | 2009-09-23 | 诺沃-诺迪斯克有限公司 | 蛋白酶抗性的胰岛素类似物 |
| JP5503968B2 (ja) | 2006-09-27 | 2014-05-28 | ノボ・ノルデイスク・エー／エス | 成熟インスリンポリペプチドの作製方法 |
| ES2425413T3 (es) | 2006-11-22 | 2013-10-15 | Novo Nordisk A/S | Método para preparar carboxipeptidasa activada |
| WO2009010428A1 (en) | 2007-07-16 | 2009-01-22 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
| ES2558930T3 (es) | 2007-08-13 | 2016-02-09 | Novo Nordisk A/S | Análogos de la insulina de acción rápida |
| WO2009022013A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| US8501449B2 (en) * | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
| EP2910571B1 (de) | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Proteasestabilisierte, acylierte insulinanaloga |
| ES2563553T3 (es) | 2008-04-01 | 2016-03-15 | Novo Nordisk A/S | Conjugados de insulina-albúmina |
| WO2010103546A2 (en) * | 2009-03-12 | 2010-09-16 | Bigtec Private Limited | A polynucleotide and polypeptide sequence and methods thereof |
| ES2543705T3 (es) | 2009-06-26 | 2015-08-21 | Novo Nordisk A/S | Preparación que contiene insulina, nicotinamida y arginina |
| WO2011064282A1 (en) | 2009-11-25 | 2011-06-03 | Novo Nordisk A/S | Method for making polypeptides |
| EP2526117B1 (de) | 2010-01-22 | 2015-05-06 | Novo Nordisk A/S | Verfahren zur herstellung von fgf-21 mit geringer o-glykosylierung |
| US8815798B2 (en) | 2010-06-23 | 2014-08-26 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| WO2011161083A1 (en) | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
| RU2598273C2 (ru) | 2010-06-23 | 2016-09-20 | Ново Нордиск А/С | Производные инсулина, содержащие дополнительные дисульфидные связи |
| RU2013130374A (ru) | 2010-12-14 | 2015-01-20 | Ново Нордиск А/С | Препарат, содержащий инсулин, никотинамид и аминокислоту |
| JP2013545782A (ja) | 2010-12-14 | 2013-12-26 | ノヴォ ノルディスク アー／エス | 長時間作用型インスリンと組み合わせた速効型インスリン |
| WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
| RU2460795C1 (ru) * | 2011-07-06 | 2012-09-10 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") | Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека |
| WO2013186138A1 (en) | 2012-06-14 | 2013-12-19 | Novo Nordisk A/S | Preparation comprising insulin, nicotinamide and arginine |
| JP6735561B2 (ja) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体 |
| CN103254277B (zh) * | 2013-05-03 | 2017-02-08 | 南京工业大学 | 强分泌性信号肽增强小肽模序及其应用 |
| JP2016521701A (ja) | 2013-06-07 | 2016-07-25 | ノヴォ ノルディスク アー／エス | 成熟インスリンポリペプチドを作製するための方法 |
| PL233560B1 (pl) | 2014-12-05 | 2019-10-31 | Mabion Spolka Akcyjna | Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka |
| EP3268384B1 (de) | 2015-03-10 | 2021-11-03 | Merck Sharp & Dohme Corp. | Verfahren zur herstellung von rekombinantem insulin unter verwendung von mikrofiltration |
| US11208452B2 (en) | 2015-06-02 | 2021-12-28 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| US20180244743A1 (en) | 2015-08-25 | 2018-08-30 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| TW201717998A (zh) | 2015-08-25 | 2017-06-01 | 諾佛 儂迪克股份有限公司 | 新穎胰島素衍生物及其醫學用途 |
| US20190010206A1 (en) | 2015-08-25 | 2019-01-10 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| KR102043067B1 (ko) * | 2017-08-08 | 2019-11-11 | 엘지전자 주식회사 | 차량용 사이드 미러 및 차량 |
| MX2020001434A (es) | 2017-08-17 | 2020-03-20 | Novo Nordisk As | Analogos de insulina acilados novedosos y usos de estos. |
| BR112022009510A2 (pt) | 2019-12-11 | 2022-08-16 | Novo Nordisk As | Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição |
| WO2023144240A1 (en) | 2022-01-26 | 2023-08-03 | Novo Nordisk Research Centre Oxford Limited | Glucose sensitive insulin derivatives and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5712580A (en) * | 1979-04-05 | 1980-10-09 | James Joseph Connell | Engine charging and scavenging |
| US4546082A (en) * | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| JPS60501140A (ja) * | 1983-04-22 | 1985-07-25 | アムジエン | 酵母による外因性ポリペプチドの分泌 |
| US4588684A (en) * | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| EP0195680A3 (de) * | 1985-03-21 | 1987-06-10 | Immunex Corporation | Proteinsynthese mit einem Identifizierungspeptid |
| JPS6236183A (ja) * | 1985-06-20 | 1987-02-17 | ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド | サツカロミセス・セレビシエからのポリペプチドの発現および分泌 |
| MC1834A1 (fr) * | 1986-07-10 | 1988-06-03 | Transgene Sa | Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation |
| US4987070A (en) * | 1987-03-04 | 1991-01-22 | Suntory Limited | Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins |
| WO1988010299A1 (en) * | 1987-06-24 | 1988-12-29 | Novo-Nordisk A/S | A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation |
| DK450187D0 (da) * | 1987-08-28 | 1987-08-28 | Novo Industri As | Fremgangsmaade til fremstilling af proteiner |
| DK463887D0 (da) * | 1987-09-07 | 1987-09-07 | Novo Industri As | Gaerleader |
| JPH01240191A (ja) * | 1988-02-16 | 1989-09-25 | Green Cross Corp:The | 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現 |
| DK336188D0 (da) * | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
| WO1990001063A1 (en) * | 1988-07-23 | 1990-02-08 | Delta Biotechnology Limited | New secretory leader sequences |
| DK105489D0 (da) * | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
-
1989
- 1989-03-03 DK DK105489A patent/DK105489D0/da not_active Application Discontinuation
-
1990
- 1990-02-27 ZA ZA901476A patent/ZA901476B/xx unknown
- 1990-03-01 WO PCT/DK1990/000058 patent/WO1990010075A1/en active IP Right Grant
- 1990-03-01 ES ES90904258T patent/ES2062514T5/es not_active Expired - Lifetime
- 1990-03-01 CA CA002050336A patent/CA2050336C/en not_active Expired - Fee Related
- 1990-03-01 KR KR1019910701029A patent/KR970005928B1/ko not_active IP Right Cessation
- 1990-03-01 HU HU902376A patent/HU215538B/hu not_active IP Right Cessation
- 1990-03-01 AU AU52612/90A patent/AU624694B2/en not_active Ceased
- 1990-03-01 DE DE69011853T patent/DE69011853T3/de not_active Expired - Lifetime
- 1990-03-01 AT AT90904258T patent/ATE110414T1/de not_active IP Right Cessation
- 1990-03-01 NZ NZ232742A patent/NZ232742A/xx unknown
- 1990-03-01 DK DK90904258.2T patent/DK0461165T3/da active
- 1990-03-01 JP JP2504527A patent/JP2609367B2/ja not_active Expired - Lifetime
- 1990-03-01 EP EP90904258A patent/EP0461165B2/de not_active Expired - Lifetime
- 1990-03-01 RU SU5010019/13A patent/RU2194758C2/ru not_active IP Right Cessation
- 1990-03-01 UA UA5010019A patent/UA27706C2/uk unknown
- 1990-03-02 DD DD90338353A patent/DD296965A5/de unknown
- 1990-03-02 CZ CS901039A patent/CZ285239B6/cs not_active IP Right Cessation
- 1990-03-02 IE IE74990A patent/IE66469B1/en not_active IP Right Cessation
- 1990-03-02 IL IL9360990A patent/IL93609A/en not_active IP Right Cessation
- 1990-03-02 PL PL90284146A patent/PL163532B1/pl not_active IP Right Cessation
-
1991
- 1991-09-02 NO NO913427A patent/NO304236B1/no unknown
- 1991-09-02 FI FI914125A patent/FI104985B/fi not_active IP Right Cessation
-
1994
- 1994-02-15 US US08/196,887 patent/US5395922A/en not_active Expired - Lifetime
-
1995
- 1995-03-02 US US08/397,595 patent/US5510249A/en not_active Expired - Lifetime
- 1995-03-02 US US08/397,597 patent/US5514585A/en not_active Expired - Lifetime
- 1995-06-29 HU HU95P/P00592P patent/HU211600A9/hu unknown
-
1997
- 1997-10-23 NO NO974899A patent/NO974899L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI104985B (fi) | Hiivan muokkausjärjestelmä, joka käsittää muokkauskohdan vieressä negatiivisesti varautuneen aminohapon | |
| JP3085973B2 (ja) | 組換え酵母による成熟タンパク質の分泌に関するシグナルペプチドについてコードする配列として新規ｄｎａ断片の適用、発現カセット、形質転換酵母及びそれに対応するタンパク質の製造方法 | |
| FI104564B (fi) | Peptidi ja DNA-sekvenssit | |
| JP3730255B2 (ja) | イーストにおいて発現されたｎ末端に伸長した蛋白質 | |
| KR100227167B1 (ko) | 인체혈청알부민의 n-말단 단편을 함유하는 융합단백질 | |
| FI104635B (fi) | Hirudiinia tuottava transformoitu hiiva ja menetelmä hirudiinin valmistamiseksi sillä | |
| HU206518B (en) | Process for producing new insuline analogues and pharmaceutical compositions containing them | |
| JPH10501413A (ja) | 合成リーダーペプチド配列類 | |
| JPS6236183A (ja) | サツカロミセス・セレビシエからのポリペプチドの発現および分泌 | |
| FI105482B (fi) | Menetelmä heterologisen proteiinin valmistamiseksi eukaryoottisessa isäntäsolussa | |
| ES2258797T3 (es) | Proteinas con extension n-terminal expresadas en la levadura. | |
| EP0437544A4 (en) | Recombinant pdgf and methods for production | |
| ES2242969T3 (es) | Vector para la expresion de proteinas con prolongacion n-terminal en celulas de levadura. | |
| EP0375718B1 (de) | Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe | |
| HUT72926A (en) | High molecular weight desulphatohirudin | |
| GB2214508A (en) | Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences. | |
| CZ20015A3 (cs) | Rekombinantní exprimovaný kvasinkový vektor, způsob jeho získávání a transformovaná kvasinková buňka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |